Zolimomab aritox

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameZolimomab aritox
Drug Alias NameOrthozyme CD5 PlusAnti-CD5 ricin A chain immunotoxinAnti-CD5 monoclonal antibody-ricin-chain-A conjugateCD5 PlusXomazyme CD5 Plus +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Toxin
Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitorsImmunosuppressants
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsRejection of renal transplantationGraft vs Host DiseaseDiabetes Mellitus +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOrtho-Mcneil IncXoma CorpCancer Research UK
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationGraft vs Host DiseaseDiabetes Mellitus +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG